Compare Cadila Healthcare with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs SUN PHARMA - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE SUN PHARMA CADILA HEALTHCARE/
SUN PHARMA
 
P/E (TTM) x 32.1 438.6 7.3% View Chart
P/BV x 4.1 2.7 152.2% View Chart
Dividend Yield % 0.8 0.6 141.9%  

Financials

 CADILA HEALTHCARE   SUN PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-20
SUN PHARMA
Mar-19
CADILA HEALTHCARE/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs352679 51.9%   
Low Rs207375 55.0%   
Sales per share (Unadj.) Rs139.2121.1 114.9%  
Earnings per share (Unadj.) Rs11.813.4 88.0%  
Cash flow per share (Unadj.) Rs18.620.7 89.8%  
Dividends per share (Unadj.) Rs3.502.75 127.3%  
Dividend yield (eoy) %1.30.5 240.1%  
Book value per share (Unadj.) Rs101.4172.6 58.7%  
Shares outstanding (eoy) m1,023.742,399.26 42.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.04.4 46.1%   
Avg P/E ratio x23.739.4 60.3%  
P/CF ratio (eoy) x15.025.5 59.0%  
Price / Book Value ratio x2.83.1 90.3%  
Dividend payout %29.820.6 144.7%   
Avg Mkt Cap Rs m286,0331,264,650 22.6%   
No. of employees `00013.417.5 76.6%   
Total wages/salary Rs m24,14559,671 40.5%   
Avg. sales/employee Rs Th10,632.716,608.1 64.0%   
Avg. wages/employee Rs Th1,801.23,409.6 52.8%   
Avg. net profit/employee Rs Th898.51,833.8 49.0%   
INCOME DATA
Net Sales Rs m142,531290,659 49.0%  
Other income Rs m1,13910,255 11.1%   
Total revenues Rs m143,670300,914 47.7%   
Gross profit Rs m24,19863,076 38.4%  
Depreciation Rs m6,96517,533 39.7%   
Interest Rs m3,4185,553 61.6%   
Profit before tax Rs m14,95450,246 29.8%   
Minority Interest Rs m2880-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-12,144 0.0%   
Tax Rs m3,1986,009 53.2%   
Profit after tax Rs m12,04432,093 37.5%  
Gross profit margin %17.021.7 78.2%  
Effective tax rate %21.412.0 178.8%   
Net profit margin %8.511.0 76.5%  
BALANCE SHEET DATA
Current assets Rs m87,154310,692 28.1%   
Current liabilities Rs m82,694173,396 47.7%   
Net working cap to sales %3.147.2 6.6%  
Current ratio x1.11.8 58.8%  
Inventory Days Days7199 72.1%  
Debtors Days Days94112 84.1%  
Net fixed assets Rs m133,236232,477 57.3%   
Share capital Rs m1,0242,399 42.7%   
"Free" reserves Rs m102,733411,691 25.0%   
Net worth Rs m103,757414,091 25.1%   
Long term debt Rs m32,14615,226 211.1%   
Total assets Rs m236,866646,938 36.6%  
Interest coverage x5.410.0 53.5%   
Debt to equity ratio x0.30 842.6%  
Sales to assets ratio x0.60.4 133.9%   
Return on assets %6.55.8 112.2%  
Return on equity %11.67.8 149.8%  
Return on capital %13.710.2 135.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m52,75266,025 79.9%   
Fx outflow Rs m14,50438,610 37.6%   
Net fx Rs m38,24827,415 139.5%   
CASH FLOW
From Operations Rs m25,05421,965 114.1%  
From Investments Rs m-10,123-6,813 148.6%  
From Financial Activity Rs m-10,942-27,305 40.1%  
Net Cashflow Rs m3,989-8,442 -47.3%  

Share Holding

Indian Promoters % 74.8 63.7 117.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 5.1 161.8%  
FIIs % 5.9 23.0 25.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 8.3 132.5%  
Shareholders   44,069 133,026 33.1%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   ALEMBIC  NEULAND LABS  PIRAMAL ENTERPRISES  FDC.  AUROBINDO PHARMA  

Compare CADILA HEALTHCARE With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 136 Points Lower; Telecom and Automobile Stocks Witness Selling(Closing)

Indian share markets witnessed volatile trading activity throughout the day and ended marginally lower.

Related Views on News

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 31.6% (Quarterly Result Update)

May 28, 2020 | Updated on May 28, 2020

For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

My View on ITC(Fast Profits Daily)

Oct 23, 2020

What do the charts say about ITC?

PSU Banks Will Move Up Again(Profit Hunter)

Oct 27, 2020

My charts tell me PSU banks are set for a rebound.

PSU Stocks Are Looking Positive Now(Fast Profits Daily)

Oct 19, 2020

Has the market changed its opinion on PSUs?

One Cycle that Defines Everything in Markets(Profit Hunter)

Oct 23, 2020

Know this cycle to boost your profits in the market.

Markets are Always Right?(The Honest Truth)

Oct 30, 2020

Ajit Dayal on why you shouldn't let your guard down as an investor.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Oct 30, 2020 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 5-YR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS